



Client Reference:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of

DANIEL R. DEAKTER

Group Art Unit: 3626

Application No.: 10/618,418

Examiner: UNKNOWN

Filed: July 11, 2003

Confirmation No.: 7063

For: **SYSTEM AND PROCESS FOR MATCHING PATIENTS WITH CLINICAL MEDICAL TRIALS**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Applicants respectfully request the Examiner return an initialed copy of the enclosed Form PTO-1449 to Applicants with the next Office communication to indicate that the reference(s) has been considered, per MPEP § 609.

The enclosed Information Disclosure Statement (with attached Form PTO-1449) is submitted for filing in the above-identified application within three months of receipt of the PCT search report for the PCT application based on this application.

This application is a continuation-in-part application which discloses and claims subject matter disclosed in an earlier filed pending application. This application is a continuation-in-part of U.S. application serial number **10/290,275** filed **November 8, 2002**. Except for the reference attached, all patent and non-patent references were previously submitted or cited in the prior application.

Except for the references not previously submitted, the references listed on Form PTO-1449 (modified) submitted herewith, were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application.

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR 1.97(e)(1).

Respectfully Submitted,




David H. Jaffer
Registration Number 32243
Customer Number: 27498

Date: January 10, 2005
PILLSBURY WINTHROP LLP
Telephone: (650) 233-4500
Facsimile: (650) 233-4545
2475 Hanover Street
Palo Alto, CA 94304-1114

CERTIFICATION UNDER 37 C.F.R. §§ 1.8

I hereby certify that, on the date shown below, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 1/10/05


Signature

DIANA DEARING



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 016351-0313132	SERIAL NO. 10/618,418
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT DANIEL DEAKTER	
		FILING DATE July 11, 2003	GROUP ART UNIT 3626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		US DOCUMENT NUMBER	DATE	NAME	CLASS/SU BCLASS	FILING DATE IF APPROPRIATE
	AA	US 6,151,581 A	11-2000	Kraftson et al.	705/3	
	AB	US 2002/0099570 A1	07-2002	Knight, Stephen C.	705/2	
	AC	US 2003/0097291 A1	05-2003	Freedman, Louis J.	70/58	
	AD	US 2002/0077853 A1	06-2002	Boru et al.	705/2	
		US				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AE	Anonymous, "R & D Directions," How to Keep Rolling in Enrollment, Engel Publishing Partners (Scot Plains, NJ), Vol. 4 (No. 2), p. 10-11, (March 1998)
AF	Baldwin, System makes it easier to link patients to clinical trials, November 1998, American Medical News, pages 25-26
AG	Clinical Trials; Comprehensive Online Resource Launched, December 2000, Angiogenesis Weekly, page 20.
AH	TVisions Wins Top Web Extranet Award; Recognized For Creative, Life-Saving Site, July 1999, page 1.
AI	Veritas Medicine Launches Comprehensive Online Clinical Trials and Treatment Resource for Chronically Ill Patients and Their Physicians, November 2000, page 1.
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.